LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Search

Quidel Corp

Slēgts

9.94 -7.36

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.9

Max

10.81

Galvenie mērījumi

By Trading Economics

Ienākumi

602M

-131M

Pārdošana

24M

724M

Peļņas marža

-18.062

Darbinieki

6,500

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+11.39% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-509M

700M

Iepriekšējā atvēršanas cena

17.3

Iepriekšējā slēgšanas cena

9.94

Quidel Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. maijs 22:15 UTC

Iegādes, apvienošanās, pārņemšana

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

2026. g. 11. maijs 23:46 UTC

Tirgus saruna

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

2026. g. 11. maijs 23:44 UTC

Tirgus saruna

Nikkei May Rise on AI Enthusiasm -- Market Talk

2026. g. 11. maijs 23:33 UTC

Tirgus saruna

Gold Rises on Possible Position Adjustments -- Market Talk

2026. g. 11. maijs 22:37 UTC

Tirgus saruna

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

2026. g. 11. maijs 22:32 UTC

Peļņas

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

2026. g. 11. maijs 22:02 UTC

Tirgus saruna
Galvenie ziņu notikumi

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

2026. g. 11. maijs 21:49 UTC

Peļņas

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

2026. g. 11. maijs 21:42 UTC

Tirgus saruna

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

2026. g. 11. maijs 21:32 UTC

Iegādes, apvienošanās, pārņemšana

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

2026. g. 11. maijs 21:31 UTC

Iegādes, apvienošanās, pārņemšana

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

2026. g. 11. maijs 21:23 UTC

Iegādes, apvienošanās, pārņemšana

CSG Systems Sale to NEC Gets CFIUS Clearance

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

2026. g. 11. maijs 21:12 UTC

Peļņas

Ovintiv 1Q Loss/Shr $2.35 >OVV

2026. g. 11. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 11. maijs 20:44 UTC

Peļņas

Steris: Board Approves New $1B Shr Repurchase Program >STE

2026. g. 11. maijs 20:43 UTC

Peļņas

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Loss/Shr $1.52 >CLSK

2026. g. 11. maijs 20:32 UTC

Peļņas

CleanSpark 2Q Rev $136.4M >CLSK

2026. g. 11. maijs 20:30 UTC

Peļņas

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Cont Ops EPS $2.24 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Rev $1.6B >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

2026. g. 11. maijs 20:30 UTC

Peļņas

Steris 4Q Adj EPS $2.83 >STE

2026. g. 11. maijs 20:22 UTC

Karstas akcijas

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

2026. g. 11. maijs 19:37 UTC

Peļņas

More Bad News at KKR's Private Credit Fund -- Barrons.com

2026. g. 11. maijs 19:32 UTC

Tirgus saruna

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Salīdzinājums

Cenas izmaiņa

Quidel Corp Prognoze

Cenas mērķis

By TipRanks

11.39% augšup

Prognoze 12 mēnešiem

Vidējais 12.03 USD  11.39%

Augstākais 13 USD

Zemākais 11 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Quidel Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

6 ratings

1

Pirkt

4

Turēt

1

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

Pamatdarbības peļņa

$

Par Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat